is predicted to decrease the exposure to ospemifene.

Study

▶ Enzalutamide is predicted to moderately decrease the

exposure to ospemifene.oStudy

▶ HIV-protease inhibitors are predicted to increase the exposure

to

Study

ospemifene. Avoid in poor CYP2C9 metabolisers.o ▶ Hormone replacement therapy potentially opposes the effects

of ospemifene. Avoid.rTheoretical

▶ Idelalisib is predicted to increase the exposure to ospemifene.

Avoid in poor CYP2C9 metabolisers.oStudy

▶ Macrolides (clarithromycin) are predicted to increase the

exposure to

o

ospemifene. Avoid in poor CYP2C9 metabolisers.

Study

▶ Mitotane is predicted to moderately decrease the exposure to

ospemifene.oStudy

▶ Nevirapine is predicted to decrease the exposure to

ospemifene.oStudy

▶ Rifampicin is predicted to moderately decrease the exposure

to ospemifene.oStudy

▶ St John’s Wort is predicted to decrease the exposure to

ospemifene.oStudy

Oxaliplatin → see platinum compounds

Oxazepam → see TABLE 11 p. 1377 (CNS depressant effects)

Oxcarbazepine → see antiepileptics

Oxybuprocaine → see anaesthetics, local

Oxybutynin → see TABLE 10 p. 1377 (antimuscarinics)

▶ Antiarrhythmics (dronedarone) are predicted to increase the

exposure to oxybutynin.nTheoretical

▶ Oxybutynin potentially increases the risk of overheating and

dehydration when given with antiepileptics (zonisamide). Avoid

in children.rTheoretical

▶ Antifungals, azoles (fluconazole, isavuconazole, posaconazole)

are predicted to increase the exposure to oxybutynin.n Theoretical

▶ Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are

predicted to increase the exposure to oxybutynin.nStudy

▶ Aprepitant is predicted to increase the exposure to oxybutynin.

nTheoretical

▶ Calcium channel blockers (diltiazem, verapamil) are predicted to

increase the exposure to oxybutynin.nTheoretical

▶ Cobicistat is predicted to increase the exposure to oxybutynin.

nStudy

▶ Crizotinib is predicted to increase the exposure to oxybutynin.

nTheoretical

▶ HIV-protease inhibitors are predicted to increase the exposure

to oxybutynin.nStudy

▶ Idelalisib is predicted to increase the exposure to oxybutynin.

nStudy

▶ Imatinib is predicted to increase the exposure to oxybutynin.

nTheoretical

▶ Macrolides (clarithromycin) are predicted to increase the

exposure to oxybutynin.nStudy

1508 Opioids — Oxybutynin BNF 78

Interactions | Appendix 1

A1

▶ Macrolides (erythromycin) are predicted to increase the

exposure to oxybutynin.nTheoretical

▶ Netupitant is predicted to increase the exposure to oxybutynin.

nTheoretical

▶ Nilotinib is predicted to increase the exposure to oxybutynin.

nTheoretical

Oxycodone → see opioids

Oxymetholone

▶ Oxymetholone

r

increases the anticoagulant effect of coumarins.

Anecdotal

▶ Oxymetholone increases the anticoagulant effect of

phenindione.rAnecdotal

Oxytetracycline → see tetracyclines

Paclitaxel → see taxanes

Palbociclib

▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,

phenytoin, primidone) are predicted to decrease the exposure

to palbociclib. Avoid.rStudy

▶ Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are

predicted to increase the exposure to palbociclib. Avoid or

adjust palbociclib dose, p. 992.rStudy

▶ Palbociclib is predicted to increase the exposure to ciclosporin.

Adjust dose.oTheoretical

▶ Cobicistat is predicted to increase the exposure to palbociclib.

Avoid or adjust palbociclib dose, p. 992.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

palbociclib. Avoid.rStudy

▶ Palbociclib is predicted to increase the exposure to

ergotamine. Adjust dose.oTheoretical

▶ Palbociclib is predicted to increase the exposure to everolimus.

Adjust dose.oTheoretical

▶ Grapefruit juice is predicted to increase the exposure to

palbociclib. Avoid.rTheoretical

▶ HIV-protease inhibitors are predicted to increase the exposure

to

Study

palbociclib. Avoid or adjust palbociclib dose, p. 992.r

▶ Idelalisib is predicted to increase the exposure to palbociclib.

Avoid or adjust palbociclib dose, p. 992.rStudy

▶ Macrolides (clarithromycin) are predicted to increase the

exposure to

r

palbociclib. Avoid or adjust palbociclib dose, p. 992.

Study

▶ Palbociclib

Study

increases the exposure to midazolam.o ▶ Mitotane is predicted to decrease the exposure to palbociclib.

Avoid.rStudy

▶ Palbociclib is predicted to increase the exposure to opioids

(alfentanil, fentanyl). Adjust dose.oTheoretical

▶ Palbociclib is predicted to increase the exposure to pimozide.

Adjust dose.oTheoretical

▶ Rifampicin is predicted to decrease the exposure to palbociclib.

Avoid.rStudy

▶ Palbociclib is predicted to increase the exposure to sirolimus.

Adjust dose.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

palbociclib. Avoid.rTheoretical

▶ Palbociclib is predicted to increase the exposure to tacrolimus.

Adjust dose.oTheoretical

Paliperidone → see TABLE 8 p. 1376 (hypotension), TABLE 9 p. 1377 (QTinterval prolongation), TABLE 11 p. 1377 (CNS depressant effects)

▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,

phenytoin, primidone) are predicted to decrease the exposure

to paliperidone. Monitor and adjust dose.rStudy → Also

see TABLE 11 p. 1377

▶ Antiepileptics (valproate) slightly increase the exposure to

paliperidone. Adjust dose.oStudy

▶ Paliperidone is predicted to decrease the effects of dopamine

receptor agonists. Avoid.oTheoretical → Also see TABLE 8

p. 1376 → Also see TABLE 9 p. 1377

▶ Enzalutamide is predicted to decrease the exposure to

paliperidone. Monitor and adjust dose.rStudy

▶ Paliperidone

r

is predicted to decrease the effects of levodopa.

Theoretical → Also see TABLE 8 p. 1376

▶ Methylphenidate increases the risk of dyskinesias when given

with paliperidone.rTheoretical

▶ Mitotane is predicted to decrease the exposure to paliperidone.

Monitor and adjust dose.rStudy

▶ Rifampicin is predicted to decrease the exposure to

paliperidone. Monitor and adjust dose.rStudy

▶ St John’s Wort is predicted to decrease the exposure to

paliperidone.rTheoretical

Palonosetron → see TABLE 9 p. 1377 (QT-interval prolongation),

TABLE 13 p. 1378 (serotonin syndrome)

▶ Dopamine receptor agonists (apomorphine) are predicted to

increase the risk of severe hypotension when given with

palonosetron.rTheoretical

Pamidronate → see bisphosphonates

Pancreatin

▶ Pancreatin is predicted to decrease the effects of acarbose.

Avoid.oTheoretical

Pancuronium → see neuromuscular blocking drugs, non-depolarising

Panitumumab → see monoclonal antibodies

Panobinostat → see TABLE 15 p. 1378 (myelosuppression), TABLE 9

p. 1377 (QT-interval prolongation)

FOOD AND LIFESTYLE Avoid pomegranate, pomegranate juice,

and star fruit as they are predicted to increase panobinostat

exposure.

▶ Antiarrhythmics (amiodarone, dronedarone) are predicted to

increase the exposure to

Theoretical → Also see TABLE 9

panobinostat

p. 1377

. Adjust dose.o ▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,

phenytoin, primidone) are predicted to decrease the exposure

to panobinostat. Avoid.oTheoretical

▶ Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are

predicted to increase the exposure to panobinostat. Adjust

panobinostat

o

dose; in hepatic impairment avoid, p. 936.

Study → Also see TABLE 9 p. 1377

▶ Antifungals, azoles (posaconazole) are predicted to increase the

exposure to panobinostat. Adjust dose.oTheoretical

▶ Panobinostat is predicted to increase the exposure to

atomoxetine. Monitor and adjust dose.rTheoretical

▶ Panobinostat is predicted to increase the exposure to beta

blockers, selective

o

(metoprolol). Monitor and adjust dose.

Theoretical

▶ Panobinostat is predicted to increase the exposure to beta

blockers, selective (nebivolol). Monitor and adjust dose.n Theoretical

▶ Calcium channel blockers (verapamil) are predicted to increase

the exposure to panobinostat. Adjust dose.oTheoretical

▶ Ciclosporin is predicted to increase the exposure to

panobinostat. Adjust dose.oTheoretical

▶ Cobicistat is predicted to increase the exposure to

panobinostat. Adjust panobinostat dose; in hepatic

impairment avoid, p. 936.oStudy

▶ Enzalutamide is predicted to decrease the exposure to

panobinostat. Avoid.oTheoretical

▶ HIV-protease inhibitors are predicted to increase the exposure

to panobinostat. Adjust panobinostat dose; in hepatic

impairment avoid, p. 936.oStudy → Also see TABLE 9

p. 1377

▶ Idelalisib is predicted to increase the exposure to

panobinostat. Adjust panobinostat dose; in hepatic

impairment avoid, p. 936.oStudy → Also see TABLE 15

p. 1378

▶ Lapatinib is predicted to increase the exposure to

panobinostat. Adjust dose.oTheoretical → Also see

TABLE 9 p. 1377

▶ Macrolides (azithromycin, erythromycin) are predicted to

increase the exposure to

Theoretical → Also see TABLE 9

panobinostat

p. 1377

. Adjust dose.o ▶ Macrolides (clarithromycin) are predicted to increase the

exposure to panobinostat. Adjust panobinostat dose; in

hepatic impairment avoid, p. 936.oStudy → Also see

TABLE 9 p. 1377

▶ Mitotane is predicted to decrease the exposure to

panobinostat. Avoid.oTheoretical → Also see TABLE 15

p. 1378

▶ Panobinostat is predicted to increase the exposure to

pimozide. Avoid.rTheoretical → Also see TABLE 9 p. 1377

BNF 78 Oxybutynin — Panobinostat 1509

Interactions | Appendix 1

A1

Panobinostat (continued)

▶ Ranolazine is predicted to increase the exposure to

panobinostat. Adjust dose.oTheoretical → Also see

TABLE 9 p. 1377

▶ Rifampicin is predicted to decrease the exposure to

panobinostat. Avoid.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

panobinostat. Avoid.oTheoretical

▶ Vemurafenib is predicted to increase the exposure to

panobinostat. Adjust dose.oTheoretical → Also see

TABLE 9 p. 1377

Pantoprazole → see proton pump inhibitors

Papaveretum → see opioids

Paracetamol → see TABLE 1 p. 1375 (hepatotoxicity)

▶ Alcohol (beverage)(in those who drink heavily) causes severe

liver damage when given with paracetamol.rStudy → Also

see TABLE 1 p. 1375

▶ Paracetamol is predicted to decrease the clearance of alkylating

agents (busulfan).oTheoretical

▶ Paracetamol is predicted to increase the risk of

methaemoglobinaemia when given with topical anaesthetics,

local (prilocaine). Use with caution or avoid.rTheoretical

▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,

phenytoin, primidone)

o

decrease the exposure to paracetamol.

Study → Also see TABLE 1 p. 1375

▶ Paracetamol

o

increases the anticoagulant effect of coumarins.

Study

▶ Paracetamol is predicted to increase the risk of

Theoretical

methaemoglobinaemia when given with dapsone.r

▶ Imatinib increases the risk of hepatotoxicity when given with

paracetamol.rAnecdotal

▶ Paracetamol potentially increases the risk of high anion gap

r

metabolic acidosis when given with penicillins (flucloxacillin).

Theoretical → Also see TABLE 1 p. 1375

▶ Paracetamol is predicted to increase the anticoagulant effect

of phenindione.rTheoretical

▶ Pitolisant is predicted to decrease the exposure to

paracetamol.nTheoretical

▶ Rifampicin

Study

decreases the exposure to paracetamol.o

Paraldehyde → see antiepileptics

Parathyroid hormone

▶ Bisphosphonates are predicted to decrease the effects of

parathyroid hormone. Avoid.oStudy

Parecoxib → see NSAIDs

Paricalcitol → see vitamin D substances

Paritaprevir

▶ Paritaprevir (with ritonavir and ombitasvir) is predicted to

increase the exposure to aliskiren.oStudy

▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,

phenytoin, primidone) are predicted to decrease the exposure

to

Study

paritaprevir (with ritonavir and ombitasvir). Avoid.r

▶ Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are

predicted to increase the exposure to

r

paritaprevir. Avoid.

Study

▶ Antifungals, azoles (posaconazole) are predicted to increase the

exposure to paritaprevir (with ritonavir and ombitasvir) and

paritaprevir (with ritonavir and ombitasvir) is predicted to

increase the exposure to antifungals, azoles (posaconazole).

Avoid.rStudy

▶ Bosentan is predicted to decrease the exposure to paritaprevir

(with ritonavir and ombitasvir). Avoid.rStudy

▶ Cobicistat is predicted to increase the exposure to paritaprevir.

Avoid.rStudy

▶ Combined hormonal contraceptives (containing

ethinylestradiol) are predicted to increase the risk of

increased ALT concentrations when given with paritaprevir

(with ritonavir and ombitasvir). Avoid.rStudy

▶ Paritaprevir (in fixed-dose combination with dasabuvir)

decreases the anticoagulant effect of coumarins

(acenocoumarol)

Anecdotal

. Monitor INR and adjust dose.r

▶ Paritaprevir (in fixed-dose combination) decreases the

anticoagulant effect of coumarins (warfarin). Monitor INR and

adjust dose.rAnecdotal

▶ Paritaprevir (with ritonavir and ombitasvir) is predicted to

increase the exposure to dabigatran.rStudy

▶ Paritaprevir (with ritonavir and ombitasvir) increases the

exposure to

o

digoxin. Monitor and adjust digoxin dose, p. 109.

Study

▶ Paritaprevir (with ritonavir and ombitasvir) is predicted to

increase the exposure to edoxaban.rStudy

▶ Efavirenz is predicted to decrease the exposure to paritaprevir

(with ritonavir and ombitasvir). Avoid.rStudy

▶ Enzalutamide is predicted to decrease the exposure to

paritaprevir

Study

(with ritonavir and ombitasvir). Avoid.r

▶ Etravirine is predicted to decrease the exposure to

paritaprevir. Avoid.rTheoretical

▶ HIV-protease inhibitors (atazanavir boosted with ritonavir)

markedly increase the exposure to paritaprevir. Avoid or give

unboosted.oStudy

▶ HIV-protease inhibitors (darunavir boosted with ritonavir)

slightly decrease the exposure to paritaprevir. Avoid or give

unboosted.oStudy

▶ HIV-protease inhibitors (fosamprenavir, tipranavir) (boosted with

ritonavir) are predicted to increase the exposure to

paritaprevir. Avoid.rStudy

▶ HIV-protease inhibitors (lopinavir boosted with ritonavir)

moderately to markedly increase the exposure to paritaprevir.

Avoid.rStudy

▶ HIV-protease inhibitors (saquinavir) are predicted to increase the

exposure to

r

paritaprevir (in fixed-dose combination). Avoid.

Study

▶ Paritaprevir is predicted to increase the exposure to idelalisib.

Avoid.rStudy

▶ Paritaprevir (with ritonavir and ombitasvir) is predicted to

increase the exposure to loop diuretics (furosemide). Adjust

dose.oTheoretical

▶ Paritaprevir (with ritonavir and ombitasvir) is predicted to

increase the exposure to loperamide.oStudy

▶ Macrolides (clarithromycin) are predicted to increase the

exposure to paritaprevir. Avoid.rStudy

▶ Macrolides (erythromycin) are predicted to increase the

exposure to paritaprevir.oTheoretical

▶ Mitotane is predicted to decrease the exposure to paritaprevir

(with ritonavir and ombitasvir). Avoid.rStudy

▶ Nevirapine is predicted to decrease the exposure to

paritaprevir

Study

(with ritonavir and ombitasvir). Avoid.r

▶ Rifampicin is predicted to decrease the exposure to

paritaprevir

Study

(with ritonavir and ombitasvir). Avoid.r

▶ St John’s Wort is predicted to decrease the exposure to

paritaprevir

Study

(with ritonavir and ombitasvir). Avoid.r

▶ Paritaprevir (in fixed-dose combination) is predicted to

increase the risk of rhabdomyolysis when given with statins

(atorvastatin). Avoid.rTheoretical

▶ Paritaprevir (with ritonavir and ombitasvir) is predicted to

increase the exposure to

Theoretical

statins (fluvastatin). Avoid.o ▶ Paritaprevir (with ritonavir and ombitasvir) increases the

exposure to

o

Comments

Search This Blog

Archive

Show more

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

ZENOXIA 15 MG, Comprimé

VOXCIB 200 MG, Gélule

Kana Brax Laberax

فومي كايند

بعض الادويه نجد رموز عليها مثل IR ، MR, XR, CR, SR , DS ماذا تعني هذه الرموز

NIFLURIL 700 MG, Suppositoire adulte

Antifongiques مضادات الفطريات

Popular posts from this blog

علاقة البيبي بالفراولة بالالفا فيتو بروتين

التغيرات الخمس التي تحدث للجسم عند المشي

إحصائيات سنة 2020 | تعداد سكَان دول إفريقيا تنازليا :

ما هو الليمونير للأسنان ؟

ACUPAN 20 MG, Solution injectable

CELEPHI 200 MG, Gélule

الام الظهر

VOXCIB 200 MG, Gélule

ميبستان

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

ZENOXIA 15 MG, Comprimé

VOXCIB 200 MG, Gélule

Kana Brax Laberax

فومي كايند

بعض الادويه نجد رموز عليها مثل IR ، MR, XR, CR, SR , DS ماذا تعني هذه الرموز

NIFLURIL 700 MG, Suppositoire adulte

Antifongiques مضادات الفطريات

Popular posts from this blog

Kana Brax Laberax

TRIPASS XR تري باس

PARANTAL 100 MG, Suppositoire بارانتال 100 مجم تحاميل

الكبد الدهني Fatty Liver

الم اسفل الظهر (الحاد) الذي يظهر بشكل مفاجئ bal-agrisi

SEDALGIC 37.5 MG / 325 MG, Comprimé pelliculé [P] سيدالجيك 37.5 مجم / 325 مجم ، قرص مغلف [P]

نمـو الدمـاغ والتطـور العقـلي لـدى الطفـل

CELEPHI 200 MG, Gélule

أخطر أنواع المخدرات فى العالم و الشرق الاوسط

Archive

Show more